Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KIF11 | P52732 | 4/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ACP1 | P24666 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | JUN | P05412 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16379971 | 0.91 | MAPT (0.57) | MAPTKIF11GPR35P2RX1LMNA | |
| SCHEMBL3482455 | 0.89 | KIF11 (0.53) | MAPTKIF11GPR35P2RX1LMNA | |
| SCHEMBL31356653 | 0.87 | MAPT (0.57) | MAPTKIF11GPR35P2RX1LMNA | |
| SCHEMBL5448110 | 0.87 | ACP1 (0.60) | MAPTKIF11GPR35P2RX1LMNA | |
| SCHEMBL7692960 | 0.83 | GPR35 (0.74) | MAPTGPR35P2RX1LMNAACP1 | |
| SCHEMBL2681462 | 0.83 | MAPT (0.78) | MAPTGPR35P2RX1LMNAACP1 | |
| SCHEMBL4099566 | 0.82 | MAPT (0.51) | MAPTGPR35P2RX1LMNAACP1 | |
| SCHEMBL167618 | 0.81 | KIF11 (0.79) | MAPTKIF11P2RX1LMNACA12 | |
| SCHEMBL11788448 | 0.81 | MAPT (0.63) | MAPTGPR35P2RX1LMNAACP1 | |
| SCHEMBL5833345 | 0.81 | GPR35 (0.66) | MAPTGPR35P2RX1LMNAACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116200157-A | Preparation method of bio-based degradable polyester pressure-sensitive adhesive | 青岛科技大学 | 2023-06-02 | — | — | CN | claimed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | claimed |
| EP-1604653-A1 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | claimed |
| US-20040116457-A1 | Agents for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | claimed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | claimed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | claimed |
| EP-1005459-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-06-07 | — | — | EP | claimed |
| WO-1999014197-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-03-25 | — | — | WO | claimed |
| CN-116875013-B | Fully degradable toughened polylactic acid material and preparation method thereof | 青岛科技大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-119684577-A | Novel bio-based thermoplastic elastomer capable of being recycled in closed loop and preparation method thereof | 青岛科技大学 | 2025-03-25 | — | — | CN | disclosed |
| CN-115725058-B | Preparation method of degradable and recyclable copolyester and application of degradable and recyclable copolyester in pressure-sensitive adhesive | 东莞市成铭胶粘剂有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116875013-A | Fully degradable toughened polylactic acid material and preparation method thereof | 青岛科技大学 | 2023-10-13 | — | — | CN | disclosed |
| CN-114479023-B | Novel bio-based degradable thermoplastic elastomer and preparation method thereof | 青岛科技大学 | 2023-09-29 | — | — | CN | disclosed |
| CN-111704714-B | Benzo five-membered and six-membered cyclic (thio) urea catalyst and application thereof in ring-opening polymerization | 浙江大学 | 2023-08-04 | — | — | CN | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1122252-A1 | NITROGENOUS FUSED HETEROCYCLE COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND AGENTS CONTAINING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | MAPT 1206/4885KIF11 1769/4885GPR35 3592/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | MAPT 1290/4885KIF11 1878/4885GPR35 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.